AU767880B2 - Multigene vectors - Google Patents

Multigene vectors Download PDF

Info

Publication number
AU767880B2
AU767880B2 AU30943/99A AU3094399A AU767880B2 AU 767880 B2 AU767880 B2 AU 767880B2 AU 30943/99 A AU30943/99 A AU 30943/99A AU 3094399 A AU3094399 A AU 3094399A AU 767880 B2 AU767880 B2 AU 767880B2
Authority
AU
Australia
Prior art keywords
gene
cancer cell
cell
expression
xxx
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU30943/99A
Other languages
English (en)
Other versions
AU3094399A (en
Inventor
Brian D. Almond
Sunil Chada
Deborah Wilson
Louis A Zumstein
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Introgen Therapeutics Inc
Original Assignee
Introgen Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Introgen Therapeutics Inc filed Critical Introgen Therapeutics Inc
Publication of AU3094399A publication Critical patent/AU3094399A/en
Application granted granted Critical
Publication of AU767880B2 publication Critical patent/AU767880B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10341—Use of virus, viral particle or viral elements as a vector
    • C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AU30943/99A 1998-03-16 1999-03-16 Multigene vectors Ceased AU767880B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US7820598P 1998-03-16 1998-03-16
US60/078205 1998-03-16
PCT/US1999/005781 WO1999047690A2 (fr) 1998-03-16 1999-03-16 Vecteurs multigenes

Publications (2)

Publication Number Publication Date
AU3094399A AU3094399A (en) 1999-10-11
AU767880B2 true AU767880B2 (en) 2003-11-27

Family

ID=22142606

Family Applications (1)

Application Number Title Priority Date Filing Date
AU30943/99A Ceased AU767880B2 (en) 1998-03-16 1999-03-16 Multigene vectors

Country Status (5)

Country Link
EP (1) EP1064392A2 (fr)
JP (1) JP2002506651A (fr)
AU (1) AU767880B2 (fr)
CA (1) CA2323112A1 (fr)
WO (1) WO1999047690A2 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3642601A (en) * 1999-11-05 2001-05-30 Avigen, Inc. Ecdysone-inducible adeno-associated virus expression vectors
CA2404235C (fr) * 2000-03-24 2010-09-21 Cell Genesys, Inc. Vecteurs adenoviraux a specificite cellulaire comprenant un site recepteur interne du ribosome
GB2362884A (en) * 2000-05-30 2001-12-05 Isis Innovation Extended duration of airway gene therapy
US6579522B1 (en) 2000-06-27 2003-06-17 Genvec, Inc. Replication deficient adenoviral TNF vector
WO2002022176A1 (fr) 2000-09-15 2002-03-21 Genvec, Inc. Procede de modulation de neovascularisation
US6656732B1 (en) 2001-05-18 2003-12-02 Isis Pharmaceuticals, Inc. Antisense inhibition of src-c expression
US7223740B2 (en) 2001-05-23 2007-05-29 Fornix Biosciences N.V. Vectors for enhanced expression of VEGF for atrial disease treatment
EP1395292B1 (fr) * 2001-05-23 2007-11-21 Fornix Biosciences N.V. Vecteurs d'expression amelioree de vegf pour le traitement de maladies
EP1262199A1 (fr) * 2001-05-23 2002-12-04 Fornix Biosciences N.V. Vecteurs pour l'expression augmentée de VEGF pour le traítement des maladies
US20030086903A1 (en) 2001-11-02 2003-05-08 Genvec, Inc. Therapeutic regimen for treating cancer
CN100543036C (zh) 2002-05-06 2009-09-23 得克萨斯州大学系统董事会 递送治疗或诊断试剂的导向蛋白质
CN1944655B (zh) * 2006-09-04 2010-05-12 王尚武 靶向性共表达新型p53和p53AIP1的重组腺病毒
AU2014246731A1 (en) * 2013-03-30 2015-11-19 Usha Biotech Limited Methods and constructs for expressing biologically active proteins in mammalian cells
US20170044496A1 (en) 2014-04-10 2017-02-16 H. Lee Moffitt Cancer Center And Research Institute, Inc. Enhanced Expansion of Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy
WO2017068614A1 (fr) * 2015-10-23 2017-04-27 徹幸 平畑 Composition de thérapie génique
CN108823208B (zh) * 2018-06-29 2021-11-02 中国科学院过程工程研究所 一种四环素诱导启动子及其制备方法和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5833975A (en) * 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
IL107250A (en) * 1993-10-12 2001-08-08 Yeda Res & Dev Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins
FR2722208B1 (fr) * 1994-07-05 1996-10-04 Inst Nat Sante Rech Med Nouveau site interne d'entree des ribosomes, vecteur le contenant et utilisation therapeutique
DE19514310A1 (de) * 1995-04-18 1996-10-24 Univ Ludwigs Albert Vektoren zur Transfektion von eukaryotischen Zellen, deren Verwendung und damit transfizierte Zielzellen
FR2755975B1 (fr) * 1996-11-15 1999-05-07 Rhone Poulenc Rorer Sa Virus recombinants bicistroniques utiles pour le traitement de pathologies liees aux dyslipoproteinemies

Also Published As

Publication number Publication date
WO1999047690A3 (fr) 1999-11-18
AU3094399A (en) 1999-10-11
JP2002506651A (ja) 2002-03-05
EP1064392A2 (fr) 2001-01-03
CA2323112A1 (fr) 1999-09-23
WO1999047690A2 (fr) 1999-09-23

Similar Documents

Publication Publication Date Title
AU767880B2 (en) Multigene vectors
US6630344B1 (en) Diminishing viral gene expression by promoter replacement
ES2338288T3 (es) Metodo mejorado para la produccion y purificacion de vectores adenovirales.
US6899870B1 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
US6740320B1 (en) Recombinant P53 adenovirus methods and compositions
CN1244215B (zh) 改进的腺病毒载体生产和纯化方法
JP2000501394A (ja) ガンの診断および処置のための方法および組成物
US6855549B1 (en) Methods and compositions for increasing the infectivity of gene transfer vectors
US6251871B1 (en) P16 expression constructs and their application in cancer therapy
AU762493B2 (en) Induction of apoptic or cytotoxic gene expression by adenoviral mediated gene codelivery
JP2005500247A (ja) ヒトｍｄａ−７に関わる処置方法
US6517828B1 (en) C-CAM as an angiogenesis inhibitor
JP2006519614A (ja) 悪性かつ形質転換した哺乳動物細胞を選択的に殺すペプチド
KR19980068555A (ko) 암 억제 단백질인 p53 을 생산하는 아데노바이러스 및 이를 항암 치료에 사용하는 용도

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)